RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Prolactinoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Hyperprolactinemia and corneal ectasia risk: A tomographic and densitometric analysis in prolactinoma patients.
Erdal Büşra D Yıldırım et al., Indian journal of ophthalmology (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42885953/
- 2.
LGALS3 Drives Dopamine Agonist Resistance in Prolactinoma by Activating the MAPK/ERK Pathway: A Multi-Omics Study.
Rao Changjun et al., Clinical endocrinology (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42873818/
- 3.
Dynamic integrated response to dopamine agonist monotherapy in Chinese men with prolactinoma: a retrospective cohort study
Hangping Zheng et al., BMC Endocrine Disorders (8 October 2026)
https://doi.org/10.1186/s12902-026-02636-w
- 4.
Macroprolactinoma with an atypical course.
Andrysiak-Mamos Elżbieta et al., Endokrynologia Polska (6 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42836731/
- 5.
Approach to the pregnant patient with prolactinoma.
Karaca Zuleyha et al., The Journal of clinical endocrinology and metabolism (3 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42828437/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Prolactinoma
Prolactinoma is a non-cancerous tumour of the pituitary gland that makes too much of the hormone prolactin. It can cause irregular or absent periods, infertility, milk production unrelated to pregnancy, reduced sex drive and, with larger tumours, headaches or vision problems. Treatment is usually with dopamine agonist medicines, with surgery or radiotherapy for some people.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
PURPOSE: To compare the corneal tomographic features of patients with prolactinoma with those of healthy controls and to assess the risk of ectasia in the corneas of patients with prolactinoma. METHODS: Forty-two patients with prolactinoma and 48 controls were included in this study. Keratometry values, thinnest corneal thickness (TCT), maximal anterior and posterior elevation values, front and back difference elevation, average and maximum pachymetric progression index (PPIavg and PPImax), maximum Ambrósio relational thickness (ARTmax), Final D, and corneal densitometry parameters were recorded using corneal tomography with the Pentacam AXL wave. RESULTS: Patients with prolactinoma exhibited significantly higher steep K (K2), maximal anterior and posterior elevations, and significantly thinner TCT values than the control group ( P = 0.039, P = 0.006, P < 0.001, and P = 0.003). The differences in front and back elevations, PPIavg, PPImax, and Final D were all significantly higher, whereas the ARTmax was significantly lower (all P < 0.05). Central density values were also notably higher in the 0-2 mm central area, 2-6 mm annular area, and entire diameter area ( P = 0.009, P = 0.008, and P = 0.045, respectively). When examining factors that affected the final D in patients with prolactinoma, age, prolactin levels at diagnosis, prolactin levels on the day of examination, duration of hyperprolactinemia, and FSH levels all showed significant effects in the univariate analysis (β = 0.048, P = 0.004; β = 0.005, P = 0.005; β = 0.006, P = 0.004; β = 0.028, P < 0.001; and β = 0.071, P = 0.009, respectively). In multivariate analysis, the duration of hyperprolactinemia also had a significant impact (β = 0.020, P = 0.022). CONCLUSIONS: The risk of ectasia may increase with prolonged elevation of prolactin levels in patients with prolactinoma.
Common Questions
What is Prolactinoma?
Prolactinoma is a non-cancerous tumour of the pituitary gland that makes too much of the hormone prolactin. It can cause irregular or absent periods, infertility, milk production unrelated to pregnancy, reduced sex drive and, with larger tumours, headaches or vision problems. Treatment is usually with dopamine agonist medicines, with surgery or radiotherapy for some people.
How many clinical trials are available for Prolactinoma?
RareWays currently indexes 16 clinical trials for Prolactinoma, of which 3 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Prolactinoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Prolactinoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.